Physician profile
Jami D Lechner
NPI 1992105191
$2,877.85
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,651 · 2022: $187 · 2023: $13.46 · 2024: $26.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $39.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $39.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $792.58 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $402.37 | 2021 | |
| Novo Nordisk INC | $348.65 | 2021-2022 | |
| Glaxosmithkline, LLC. | $273.68 | 2021 | |
| Viiv Healthcare Company | $231.05 | 2021 | |
| Abbott Laboratories | $173.06 | 2021 | |
| Radius Health, INC. | $114.78 | 2021 | |
| Amgen INC. | $107.95 | 2021 | |
| Lilly USA, LLC | $68.37 | 2021 | |
| Astellas Pharma US INC | $68.30 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.16 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $57.30 | 2021 | |
| Daiichi Sankyo INC. | $46.02 | 2021 | |
| Jazz Pharmaceuticals INC. | $40.55 | 2021 | |
| Avanir Pharmaceuticals, INC. | $28.89 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $16.63 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.31 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.27 | 2021 | |
| Gilead Sciences, INC. | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jami Lechner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.